A great opportunity for presenting both EPAD and its sister project AMYPAD happened in Boston where the 10th Clinical Trials on Alzheimer’s Disease (CTAD) conference took place from 1 to 4 November.

AMYPAD works closely with the EPAD project, which is working to increase the understanding of the early stages of Alzheimer’s disease and creating a platform to test treatments designed to prevent dementia. The AMYPAD Prognostic and Natural History Study (PNHS) is planned as a sub-study of the EPAD Longitudinal Cohort Study (LCS). In the AMYPAD PNHS study, participants enrolled in the EPAD LCS will undergo PET amyloid imaging.

We are delighted that AMYPAD was mentioned in a plenary lecture entitled “The European Prevention of Alzheimer’s Dementia (EPAD) and Amyloid Imaging for Prevention of Alzheimer’s Dementia (AMYPAD) Projects: Cohort Readiness for the Adaptive Clinical Trial Platform.”
Craig Ritchie (pictured) from The University of Edinburgh (EPAD Coordinator and AMYPAD WP4 co-lead) presented the first data analysis from EPAD LCS at CTAD.

To access the conference website, please visit http://www.ctad-alzheimer.com/

The first analysis of EPAD LCS Data can be read on the EPAD website.

The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.
The AMYPAD project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. The Joint Undertaking receives support from the European Union’s Horizon2020 research and innovation programme and EFPIA.